» Articles » PMID: 8548757

An Engineered Four-stranded Coiled Coil Substitutes for the Tetramerization Domain of Wild-type P53 and Alleviates Transdominant Inhibition by Tumor-derived P53 Mutants

Overview
Journal Cancer Res
Specialty Oncology
Date 1996 Jan 1
PMID 8548757
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The tetramerization domain of p53 is required for efficient tumor suppressor activity. This domain, however, also allows wild-type p53 to heterooligomerize with dominant negative tumor-derived p53 mutants. We explored the feasibility of substituting the native tetramerization domain of wild-type p53 with an engineered leucine zipper that assembles as a four-stranded coiled coil. The engineered zipper drove p53 tetramerization in vitro and p53 function in vivo. Furthermore, it alleviated transdominant inhibition by tumor-derived p53 mutants, implying that dominant negative mutants act by hetero-oligomerizing with wild-type p53. The ability of the engineered zipper to drive tetramerization was critical for p53 function, since p53 dimers, formed by substituting the p53 tetramerization domain with a native leucine zipper, were weak tumor suppressors.

Citing Articles

The Role of p53 in Nanoparticle-Based Therapy for Cancer.

Szewczyk-Roszczenko O, Barlev N Cells. 2023; 12(24).

PMID: 38132123 PMC: 10742014. DOI: 10.3390/cells12242803.


Evaluating different DNA binding domains to modulate L1 ORF2p-driven site-specific retrotransposition events in human cells.

Ade C, Derbes R, Wagstaff B, Linker S, White T, Deharo D Gene. 2017; 642:188-198.

PMID: 29154869 PMC: 5734997. DOI: 10.1016/j.gene.2017.11.033.


Selectivity in subunit composition of Ena/VASP tetramers.

Riquelme D, Meyer A, Barzik M, Keating A, Gertler F Biosci Rep. 2015; 35(5).

PMID: 26221026 PMC: 4721544. DOI: 10.1042/BSR20150149.


Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.

Okal A, Matissek K, Matissek S, Price R, Salama M, Janat-Amsbury M Gene Ther. 2014; 21(10):903-12.

PMID: 25077773 PMC: 4324557. DOI: 10.1038/gt.2014.70.


Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.

Okal A, Cornillie S, Matissek S, Matissek K, Cheatham 3rd T, Lim C Mol Pharm. 2014; 11(7):2442-52.

PMID: 24836513 PMC: 4114475. DOI: 10.1021/mp500202p.